Cart
sales@molnova.com
Salvianolic acid A
CAS No. 96574-01-5
Salvianolic acid A( Dan Phenolic Acid A )
Catalog No. M19895 CAS No. 96574-01-5
Salvianolic acid A could protect the blood brain barrier through matrix metallopeptidase 9 (MMP-9) inhibition and anti-inflammation.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 46 | In Stock |
|
| 5MG | 43 | In Stock |
|
| 10MG | 68 | In Stock |
|
| 25MG | 139 | In Stock |
|
| 50MG | 202 | In Stock |
|
| 100MG | 303 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSalvianolic acid A
-
NoteResearch use only, not for human use.
-
Brief DescriptionSalvianolic acid A could protect the blood brain barrier through matrix metallopeptidase 9 (MMP-9) inhibition and anti-inflammation.
-
DescriptionSalvianolic acid A could protect the blood brain barrier through matrix metallopeptidase 9 (MMP-9) inhibition and anti-inflammation.(In Vivo):A significant beneficial effect of Salvianolic acid A (SAA) is observed in the Salvianolic acid A treatment groups. Salvianolic acid A (20 mg/kg) could significantly prolonged the retention time of rats on the plate. While compared with sham operation group, the brain water content in model group significantly increases, which is attenuated significantly by Salvianolic acid A (10 and 20 mg/kg). Compared with the model group, Salvianolic acid A (5, 10, and 20 mg/kg) could maintain the normal structures of neurons and increase neurons number. It is also found that Salvianolic acid A (20 mg/kg) could significantly reduce I/R induced MMP-9 upregulation. While the MMP-2 expression is not significantly affected by Salvianolic acid A. Tissue inhibitors of metalloproteinases (TIMPs) could inhibit the activity of MMPs through high affinity binding to MMPs catalytic domain.
-
In Vitro——
-
In VivoA significant beneficial effect of Salvianolic acid A (SAA) is observed in the Salvianolic acid A treatment groups. Salvianolic acid A (20 mg/kg) could significantly prolonged the retention time of rats on the plate. While compared with sham operation group, the brain water content in model group significantly increases, which is attenuated significantly by Salvianolic acid A (10 and 20 mg/kg). Compared with the model group, Salvianolic acid A (5, 10, and 20 mg/kg) could maintain the normal structures of neurons and increase neurons number. It is also found that Salvianolic acid A (20 mg/kg) could significantly reduce I/R induced MMP-9 upregulation. While the MMP-2 expression is not significantly affected by Salvianolic acid A. Tissue inhibitors of metalloproteinases (TIMPs) could inhibit the activity of MMPs through high affinity binding to MMPs catalytic domain.
-
SynonymsDan Phenolic Acid A
-
PathwayMetabolic Enzyme/Protease
-
TargetMMP
-
RecptorMMP-9
-
Research AreaMetabolic Disease
-
IndicationDiabetes
Chemical Information
-
CAS Number96574-01-5
-
Formula Weight494.45
-
Molecular FormulaC26H22O10
-
Purity>98% (HPLC)
-
SolubilityDMSO:130 mg/mL; Ethanol:10 mg/mL
-
SMILESOC(=O)[C@@H](Cc1ccc(O)c(O)c1)OC(=O)\C=C\c1ccc(O)c(O)c1\C=C\c1ccc(O)c(O)c1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Zhang W et al. Salvianolic acid A attenuates ischemia reperfusion induced rat brain damage by protecting the blood brain barrier through MMP-9 inhibition and anti-inflammation. Chin J Nat Med. 2018 Mar;16(3):184-193.
molnova catalog
related products
-
Lucidenic acid C
Lucidenic acid C is a natural compound isolated from Ganoderma lucidum, inhibits PMA-induced MMP-9 activity, with anti-invasive effect on hepatoma cells.
-
Cipemastat
Cipemastat (Ro 32-3555) is a potent, second-generation, orally active MMP inhibitor.
-
Aderamastat
Aderamastat (FP-025) is an orally active matrix metalloproteinase 12 (MMP-12) inhibitor used for research in allergic asthma, COPD, and pulmonary fibrosis.
